VistaGen Therapeutics
VTGN
43 hedge funds and large institutions have $56.3M invested in VistaGen Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 6 closing their positions.
246% more call options, than puts
Call options by funds: $2.09M | Put options by funds: $606K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 42 → 43 (+1)
3.52% less ownership
Funds ownership: 63.97% → 60.44% (-3.5%)
38% less capital invested
Capital invested by funds: $90.8M → $56.3M (-$34.5M)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$235K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$86.6K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$74.1K |
| 4 |
VF
Virtu Financial
New York
|
+$67.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$62.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.43M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$969K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$495K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$475K |
| 5 |
Two Sigma Investments
New York
|
-$333K |
VTGN Hedge Fund Activity: Q2 2024 in Review
43 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2024, worth a combined $56.3M — down 38% from $90.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VTGN positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $235K. The largest seller was Great Point Partners, cutting an estimated $1.43M.
- 43 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2024, up from 42 in Q1 2024.
- Funds reported $56.3M of VistaGen Therapeutics stock for Q2 2024, down 38% quarter-over-quarter.
- 7 funds opened new VistaGen Therapeutics positions in Q2 2024 and 6 closed out, a net change of +1 holder.
- The largest VistaGen Therapeutics buyer in Q2 2024 was BlackRock, an estimated $235K added.
- The largest VistaGen Therapeutics seller in Q2 2024 was Great Point Partners, an estimated $1.43M sold.
Based on aggregated 13F filings for Q2 2024.